Literature DB >> 10717487

Few oligo-amenorrheic athletes have vasomotor symptoms.

M L Hammar1, M B Hammar-Henriksson, J Frisk, A Rickenlund, Y A Wyon.   

Abstract

OBJECTIVE: To assess whether women with athletic oligo-amenorrhea have vasomotor symptoms.
MATERIAL AND METHODS: A mailed questionnaire was sent to 252 female athletes about vasomotor symptoms. Identical questions were also mailed to 1523 peri- and postmenopausal women.
RESULTS: The prevalence of vasomotor symptoms was low in female athletes with oligo- and amenorrhea and similar to that found in athletes with regular menstruations. The prevalence was significantly lower than in menopausal women. Although more than a third of the menopausal women had hormone replacement therapy, 30% of them still had vasomotor symptoms at least every week compared with only 2% of the oligo-amenorrheic athletes.
CONCLUSION: Vasomotor symptoms are very uncommon in oligo-amenorrheic athletes, although many of them are hypoestrogenic. It was suggested that one factor contributing to these symptoms around menopause is low hypothalamic activity of beta-endorphins, which makes the thermoregulatory centre labile. On the other hand, supraphysiological activity in hypothalamic beta-endorphins may cause the oligo-amenorrhea in athletes, but may stabilise the thermoregulatory centre and thus prevent hot flushes.

Entities:  

Mesh:

Year:  2000        PMID: 10717487     DOI: 10.1016/s0378-5122(99)00115-2

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  2 in total

1.  Low body weight and menstrual dysfunction are common findings in both elite and amateur ballet dancers.

Authors:  E Bacchi; G Spiazzi; G Zendrini; C Bonin; P Moghetti
Journal:  J Endocrinol Invest       Date:  2012-10-01       Impact factor: 4.256

2.  Resistance training reduced luteinising hormone levels in postmenopausal women in a substudy of a randomised controlled clinical trial: A clue to how resistance training reduced vasomotor symptoms.

Authors:  Sigrid Nilsson; Moa Henriksson; Emilia Berin; David Engblom; Anna-Clara Spetz Holm; Mats Hammar
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.